Drug Profile
Mevidalen - Eli Lilly and Company
Alternative Names: D1 PAM; LY-3154207; Mevidalen hydroxybenzoate - Eli Lilly and CompanyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Antiparkinsonians; Chlorinated hydrocarbons; Isoquinolines; Ketones; Small molecules
- Mechanism of Action Dopamine D1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lewy body disease
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Lewy body disease(Combination therapy, In volunteers) in USA (PO, Capsule)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Lewy body disease(Combination therapy, In volunteers) in USA (PO, Tablet)
- 28 Jan 2022 Eli Lilly and Company completes a phase I trial in Lewy body disease (In volunteers, In adults) in USA (PO) (NCT04258826)